Company: PRME
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001193125-25-122158
Chunk: 6

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 6
---
. Dr. Reine’s biography is set forth in the Company’s definitive proxy statement for its 2025 annual meeting of stockholders filed pursuant to Regulation 14A on April 22, 2025.

The foregoing summary of the Reine Employment Agreement does not purport to be complete and is qualified in
its entirety by reference to the full text of the Reine Employment Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30,
2025.

Item 7.01 Regulation FD Disclosure.

On
May 19, 2025, the Company issued press releases titled “Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic
Granulomatous Disease” and “Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition.” A copy of each press
release is furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K, which is incorporated herein by reference.

On May 19, 2025, the Company posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the
corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company’s website is for inactive textual reference only
and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3
attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

Appointment of Executive Chair

On May 16, 2025, the Board appointed Jeffrey Marrazzo, a member